These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension. Gessler T; Seeger W; Schmehl T Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738 [TBL] [Abstract][Full Text] [Related]
5. Plain language summary of the INCREASE study: inhaled treprostinil (Tyvaso) for the treatment of pulmonary hypertension due to interstitial lung disease. West N; Smoot K; Patzlaff N; Miceli M; Waxman A Future Cardiol; 2023 Apr; 19(5):229-239. PubMed ID: 37466095 [TBL] [Abstract][Full Text] [Related]
6. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. McLaughlin VV; Palevsky HI Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307 [TBL] [Abstract][Full Text] [Related]
7. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Ferrantino M; White RJ Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216 [TBL] [Abstract][Full Text] [Related]
8. Treprostinil for the treatment of pulmonary arterial hypertension. Torres F; Rubin LJ Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441 [TBL] [Abstract][Full Text] [Related]
9. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. Waxman A; Restrepo-Jaramillo R; Thenappan T; Ravichandran A; Engel P; Bajwa A; Allen R; Feldman J; Argula R; Smith P; Rollins K; Deng C; Peterson L; Bell H; Tapson V; Nathan SD N Engl J Med; 2021 Jan; 384(4):325-334. PubMed ID: 33440084 [TBL] [Abstract][Full Text] [Related]
10. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension. Budev MM; Minai OA; Arroliga AC Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531 [TBL] [Abstract][Full Text] [Related]
11. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date. Cassady SJ; Almario JAN; Ramani GV Drug Healthc Patient Saf; 2024; 16():51-59. PubMed ID: 38855777 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Krishnan U; Takatsuki S; Ivy DD; Kerstein J; Calderbank M; Coleman E; Rosenzweig EB Am J Cardiol; 2012 Dec; 110(11):1704-9. PubMed ID: 22917554 [TBL] [Abstract][Full Text] [Related]
15. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098 [TBL] [Abstract][Full Text] [Related]
16. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262 [TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study. Ismat FA; Usansky HH; Villa R; Zou J; Teper A Adv Ther; 2022 Nov; 39(11):5144-5157. PubMed ID: 36070132 [TBL] [Abstract][Full Text] [Related]
18. Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality. Nathan SD; Johri S; Joly JM; King CS; Raina A; McEvoy CA; Lee D; Shen E; Smith P; Deng C; Waxman AB Thorax; 2024 Mar; 79(4):301-306. PubMed ID: 37979971 [TBL] [Abstract][Full Text] [Related]
19. Inhaled treprostinil for the treatment of pulmonary arterial hypertension. LeVarge BL; Channick RN Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940 [TBL] [Abstract][Full Text] [Related]
20. Experiences with treprostinil in the treatment of pulmonary arterial hypertension. Stream AR; Bull TM Ther Adv Respir Dis; 2012 Oct; 6(5):269-76. PubMed ID: 22868690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]